HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of disopyramide in conversion and prophylaxis of post-thyrotoxic atrial fibrillation.

Abstract
Rhythm conversion in patients with post-thyrotoxic atrial fibrillation (AF) has been performed with disopyramide in order to evaluate the conversion rate and to test its effect on the maintenance of sinus rhythm after cardioversion. The duration of AF ranged from 9 to 122 months (mean 31.8 months). Of 81 patients, 12 (15%) with relatively short duration AF were converted to sinus rhythm with disopyramide. The remaining 69 patients required DC cardioversion, which restored sinus rhythm in 58 patients. The 58 DC-converted patients were divided into two groups: a disopyramide group (D group) and a non-disopyramide group (non-D group). The D group received disopyramide 300 mg per day for 3 months after DC cardioversion and the non-D group did not receive anti-arrhythmic drugs. During the early observation period, only one patient relapsed in the D group into AF, but 5 successive patients in the non-D group reverted to AF, forcing discontinuation of the non-D protocol. A second DC cardioversion performed on 3 of those 5 patients was followed by maintenance therapy with disopyramide 300 mg per day, and they remained in sinus rhythm. With the inclusion of those three subjects, sinus rhythm was still present in 44 of the total of 58 patients converted by DC (76%) at the time of follow-up (64 months). Thus, disopyramide was effective in rhythm conversion and it was essential for the maintenance of sinus rhythm after cardioversion in patients with post-thyrotoxic AF.
AuthorsH Nakazawa, N Ishikawa, J Noh, T Sugimoto, M Yoshimoto, T Yashiro, O Ozaki, K Ito
JournalEuropean journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 40 Issue 3 Pg. 215-9 ( 1991) ISSN: 0031-6970 [Print] Germany
PMID2060555 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Disopyramide
Topics
  • Adolescent
  • Adult
  • Aged
  • Atrial Fibrillation (drug therapy, etiology, prevention & control)
  • Disopyramide (adverse effects, therapeutic use)
  • Electric Countershock (adverse effects)
  • Humans
  • Premedication
  • Thyroid Diseases (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: